Aurinia Pharmaceuticals (NASDAQ:AUPH) Cut to “Buy” at StockNews.com

StockNews.com downgraded shares of Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) from a strong-buy rating to a buy rating in a research note released on Monday morning.

Aurinia Pharmaceuticals Stock Up 2.6 %

AUPH stock opened at $7.81 on Monday. The company has a quick ratio of 5.11, a current ratio of 5.60 and a debt-to-equity ratio of 0.17. The business has a 50 day moving average price of $8.55 and a two-hundred day moving average price of $7.60. The company has a market cap of $1.12 billion, a price-to-earnings ratio of -52.06 and a beta of 1.22. Aurinia Pharmaceuticals has a twelve month low of $4.71 and a twelve month high of $10.67.

Institutional Trading of Aurinia Pharmaceuticals

A number of hedge funds have recently made changes to their positions in AUPH. Arrowstreet Capital Limited Partnership acquired a new stake in shares of Aurinia Pharmaceuticals in the fourth quarter valued at approximately $9,662,000. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in Aurinia Pharmaceuticals during the 3rd quarter worth approximately $3,330,000. JPMorgan Chase & Co. lifted its holdings in Aurinia Pharmaceuticals by 84.4% during the 4th quarter. JPMorgan Chase & Co. now owns 927,298 shares of the biotechnology company’s stock worth $8,327,000 after purchasing an additional 424,482 shares during the last quarter. Barclays PLC lifted its holdings in Aurinia Pharmaceuticals by 187.6% during the 3rd quarter. Barclays PLC now owns 219,331 shares of the biotechnology company’s stock worth $1,607,000 after purchasing an additional 143,072 shares during the last quarter. Finally, PDT Partners LLC lifted its holdings in Aurinia Pharmaceuticals by 76.0% during the 3rd quarter. PDT Partners LLC now owns 301,553 shares of the biotechnology company’s stock worth $2,210,000 after purchasing an additional 130,204 shares during the last quarter. 36.83% of the stock is owned by institutional investors and hedge funds.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.